Background: Hepcidin-25 is a key regulatory hormone of iron homeostasis in humans, and its production is greatly upregulated by inflammation as well as iron overload. The aim of this study was to investigate the pathophysiological role of hepcidin-25 in patients with systemic inflammatory response syndrome (SIRS).
Introduction
Hepcidin is a 25-amino acid peptide hormone and plays a significant role in iron homeostasis in humans 1 . The bioactive hepcidin-25 is synthesized predominantly in the liver and its N-terminal processing results in smaller isoforms (hepcidin-24, -23, -22, and -20) with greatly reduced activity that accumulate in the urine 2 4 . It induces internalization and degradation of the cellular iron exporter, ferroportin, on enterocytes, macrophages, and hepatocytes 5, 6 . Therefore, increased hepcidin-25 production leads to a decrease in serum iron concentrations and an increase in iron storage as ferritin 7 . Recent studies have suggested that hepcidin-25 plays a key role in hostpathogen interface. Iron is essential for the survival and growth of bacteria. When the bacteria infect macrophages, macrophages release a number of cytokines, including IL-6, which increase production of hepcidin-25 in hepatocytes. This up-regulation of hepcidin-25 leads to iron depletion and inhibition of bacterial growth 8, 9 .
Systemic inflammatory response syndrome (SIRS) may occur in several conditions related to bacterial infection, viral infection, autoimmune disorders, and malignancy.
In humans, increased serum hepcidin-25 levels were noted in patients with chronic infections and severe in-flammatory diseases where inflammatory cytokines play a pivotal role 10 . Inflammation-induced hepcidin-25 was also demonstrated and associated with the development of anemia in septic patients 11 . Although hepcidin-25 appears to be involved in such various inflammatory diseases and is considered as a component of innate immunity, there are no clinical studies that have comprehensively examined an association between hepcidin-25 levels and the severity of inflammation that occurs from miscellaneous causes, regardless of bacterial infection.
Therefore, the aim of this study was to elucidate the clinical importance of serum hepcidin-25 levels in patients with SIRS.
Materials and Methods

Patients and Sampling
This observational study was carried out between Au- 
Statistical Analysis
All statistical analyses and data management were per- 
Results
Demographic Information, Laboratory Data, and Blood Culture Results
Demographic information and laboratory results of each patient group are shown in Table 1 . Although the patients in the non-bacterial infection group appeared to be younger than those of either the bacteremia-or culture-negative group, that was not statistically significant. Three patients died during hospitalization: two from sepsis (bacteremia group) and one from intravascular lymphoma (non-bacterial infection group). There were also no significant differences among the 3 groups in gender, WBC, hemoglobin concentrations, and serum levels of albumin and UIBC. However, values for neutrophil differential, blood urea nitrogen, creatinine, and CRP were significantly higher in the bacteremia group than in the other groups. Instead, both iron and ferritin levels were significantly lower in the bacteremia group than in the other groups. Blood culture results are presented in Table 2 . The major pathogen identified by blood culture was Escherichia coli, followed by β-Streptococcus. One case was positive for both Klebsiella pneumoniae and Enterococcus faecalis, indicating a co-infection.
Hepcidin-25 Levels and SIRS Scores
Hepcidin-25 levels on day 1 were 162 [2. (Fig. 1) . There was no association between hepcidin-25 levels and SIRS scores.
Hepcidin-25 Levels with or without Bacteremia
The hepcidin-25 levels on day 1 were significantly (Fig. 2) . Nevertheless, there was no significant difference in the maximum hepcidin-25 levels among the 3 groups.
Correlation between Hepcidin-25 Levels and Other
Parameters
The correlations between the serum hepcidin-25 levels on day 1 and parameters of inflammation and ferrokinetics are shown in Table 3 and 
Discussion
The present study is the first to examine the pathophysiologic relevance of hepcidin-25 in patients with SIRS from various causes, including bacterial/viral infection and non-infectious diseases. Although hepcidin-25 levels
were not associated with the number of SIRS criteria present, they were significantly higher in patients with bacteremia than in those without. As noted earlier, hepcidin-25 may be involved in various inflammatory diseases. In animal models, infections or stimuli that invoke a systemic inflammatory response are likely to induce liver hepcidin expression, reduce serum iron, and increase iron accumulation as ferritin in reticuloendothelial cells 15 . Thus, it is reasonable to assume that the extent of hepcidin upregulation and resultant hypoferremia is greater if the inflammatory response becomes more vigorous. However, only a limited number of studies have tested this hypothesis in humans. An observational study in septic patients suggested that hepcidin levels correlated with the number of extended SIRS criteria and levels of IL-6 and that hepcidin was associated with development of anemia 11 . Our study failed to show a significant relationship between hepcidin-25 levels and the number of SIRS criteria. This discrepancy could be explained by the difference in patient selection and definition of SIRS: they analysed septic patients alone using the extended SIRS criteria, whereas we applied the classical criteria to the patients with various causes, including non-bacterial infection. Although SIRS criteria have been proposed as a useful index of severity for critically ill patients 16 , it does not necessarily mean This study has some unavoidable limitations. First, we were unable to strictly distinguish patients with prehospital treatments (e.g. physical cooling, antipyretic/antimicrobial agents) from those without, which might have affected the SIRS scores on admission and the result of blood cultures. Second, this was a single-center study, and its sample size was relatively small. Thus, further study with a larger sample size is needed to confirm the results. Thirdly, because we considered that CRP could be a reasonable surrogate marker for inflammation, we did not measure IL-6, a key mediator necessary for hepcidin-25 production. Although IL-6 is thought to be the main mediator of CRP production, other cytokines such as tumor necrosis factor, IL-1, and transforming growth factor-α are also involved. Therefore, the results should be interpreted with caution.
As far as our best knowledge from the literature, there has been no previous study to look into hepcidin-25 levels in patients with SIRS, including non-infectious diseases. As expected from the iron-infection axis, hepcidin-25 seems to play a substantial role in host-defense, especially in patients with bacteremia or sepsis. Our findings also suggest that upregulation of hepcidin-25 should occur even in patients without bacterial infection in proportion to the degree of the systemic inflammatory response.
Further studies need to be carried out to investigage the pathophysiologic role of hepcidin-25 in SIRS, especially from non-infectious causes.
